Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach

OBJECTIVE: To clarify the oncological benefit of zoledronic acid for hormone-naïve metastatic prostate cancer, patient outcome of androgen deprivation therapy with zoledronic acid (ADT + Z) and androgen deprivation therapy alone (ADT) was compared. METHODS: Fifty-two patients with pathologically con...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagao, Kazuhiro, Matsuyama, Hideyasu, Nozawa, Masahiro, Hara, Isao, Nishioka, Tsukasa, Komura, Takahiro, Esa, Atsunobu, Uejima, Shigeya, Imanishi, Masaaki, Uekado, Yasunari, Ogawa, Takatoshi, Kajikawa, Hiroshi, Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730815/
https://www.ncbi.nlm.nih.gov/pubmed/29264160
http://dx.doi.org/10.1016/j.ajur.2015.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730815/
https://www.ncbi.nlm.nih.gov/pubmed/29264160
http://dx.doi.org/10.1016/j.ajur.2015.10.003

Ejemplares similares